Zura Bio's Phase 2 TibuSHIELD Misses Primary Endpoint; HS Program Discontinued
ZURA is trading near its 52-week low of $3.25 (63% below the low).
Summary
Zura Bio's Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa missed its primary endpoint and key secondary endpoints, and the company is discontinuing development in HS. The SSc and PMR programs continue, backed by $187.7 million in cash through at least the end of 2028. Shares fell more than 70% in premarket trading after the miss.
Updated with a Reuters report · What changed
Updates
· Reuters — Zura Bio shares fell more than 70% in premarket trading after tibulizumab missed the Phase 2 hidradenitis suppurativa trial's primary and key secondary goals.
- Trial enrolled 247 adults with moderate-to-severe hidradenitis suppurativa, randomly assigned to one of two doses of tibulizumab or placebo.
Key Events · Product Development and Regulatory · ZURA
-
New · · Reuters
Shares Fall More Than 70% Premarket
Zura Bio shares fell more than 70% in premarket trading after tibulizumab missed the Phase 2 hidradenitis suppurativa trial's primary and key secondary goals. The trial enrolled 247 adults with moderate-to-severe hidradenitis suppurativa, randomly assigned to one of two doses of tibulizumab or placebo.
-
TibuSHIELD Fails Primary Endpoint
Week 16 AN-count reduction was 56.0% (300 mg) and 58.1% (150 mg) versus 52.5% for placebo; HiSCR50 was 48.0% and 52.7% versus 45.5%, and HiSCR75 was 35.3% and 34.0% versus 28.1%.
-
HS Development Discontinued
Zura is discontinuing development of tibulizumab in hidradenitis suppurativa and running additional PK/PD and exposure-response analyses.
-
Safety Consistent With Prior Profiles
TEAEs occurred in 52.4% of both tibulizumab arms versus 46.3% on placebo; one death in the 300 mg arm was judged unrelated to treatment.
-
Remaining Pipeline Timeline
TibuSURE topline data in systemic sclerosis expected H1 2027; NEXUS-PMR in polymyalgia rheumatica planned to start by year-end 2026 with data expected Q4 2028.
Analysis · ZURA · Life Sciences
The lead asset has failed its largest controlled study. At Week 16, AN-count reduction was 56.0% on 300 mg and 58.1% on 150 mg versus 52.5% on placebo, while HiSCR50 came in at 48.0% and 52.7% against 45.5% for placebo — differences too small to support a filing, so Zura is dropping hidradenitis suppurativa entirely. The trial enrolled 247 adults with moderate-to-severe hidradenitis suppurativa, randomly assigned to one of two doses of tibulizumab or placebo, and the market reaction was severe: shares fell more than 70% in premarket trading. That removes the indication the HS program was built around and shifts the entire thesis onto systemic sclerosis (TibuSURE topline in H1 2027) and polymyalgia rheumatica (NEXUS-PMR to start by year-end 2026, data expected Q4 2028). The cushion here is financial, not clinical: $187.7 million of cash as of September 30, 2026 is expected to fund operations through at least the end of 2028, so this result forces no near-term financing. Safety was clean — TEAEs of 52.4% in both active arms versus 46.3% on placebo — meaning the failure is about efficacy, not tolerability.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 51.3% of the 191 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZURA was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $394M. The 52-week trading range was $3.25 to $7.44. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.